Astragalus-polysaccharide-Astragalus-Polysacharin-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAstragalus polysaccharideCat. No.: HY-N0937Synonyms: Astragalus Polysacharin作靶點: PPAR作通路: Cell Cycle/DNA Damage儲存式: 4C, sealed storage, away from moisture* In solvent : -80C, 6 months; -20C, 1 month (sealedstorage, away from moi

2、sture)溶解性數(shù)據(jù)體外實驗 H2O : 20 mg/mL (Need ultrasonic)DMSO : 16.67 mg/mL (Need ultrasonic)請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當天使；澄清的儲備液可以根據(jù)儲存條件，適當保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-8

3、0 45% salineSolubility: 1.67 mg/mL (Infinity mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 1.67 mg/mL (Infinity mM); Clear solution3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 1.67 mg/mL (Infinity mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Astragalus polysaccharide

4、是黃芪多糖提取物中的活性成分，能夠激活 3T3-L1 脂肪細胞中的 PPAR- 和PI3K/Akt 。IC50 & Target PPAR-體外研究Astragalus Polysaccharides (APS) are active components of the polysaccharides extract of Astragulus, whichhas important antioxidant, anti-hypertensive, and immunomodulatory roles. Astragalus Polysaccharides1/3 Master of Small

5、Molecules 您邊的抑制劑師www.MedChemE(APS) attenuates TNF-induced insulin resistance by suppressing miR-721 and activating PPAR- andPI3K/Akt in 3T3-L1 adipocytes. Astragalus Polysaccharides (APS) has a strong anti-inflammatory effect, andenhances the gene expression of an inflammatory marker peroxisome prol

6、iferator-activated receptor gamma(PPAR-) in a time- and dose-dependent manner. Astragalus Polysaccharides (APS) reverses the PPAR-mediated suppression of genes involved in glucose utilization. The expression of miR-721 is suppressed byAstragalus Polysaccharides (APS) in a dose-dependent manner. Also

7、, the expression of PPAR- wasincreased in a dose-dependent manner. Treatment with Astragalus Polysaccharides (APS) attenuates themiR-721-inhibited expressions of PPAR-, p-Akt, and GLUT4. In the presence of insulin, AstragalusPolysaccharides (APS) upregulates the expression of PPAR-, p-Akt, PI3K, and

8、 GLUT4 in the miR-721mimics. The expression levels of PPAR-, p-Akt, PI3K, and GLUT4 in miR-721+Astragalus Polysaccharides(APS)+insulin group are lower than that in the Astragalus Polysaccharides (APS)+insulin group 1.體內(nèi)研究 To determine whether Astragalus Polysaccharides (APS) could preserve heart fun

9、ction in vivo, a heart failuremodel is generated using Doxorubicin-treated C57BL/6 mice. As shown by H&E staining, Doxorubicin-induced heart failure is associated with decreased thickening of the left ventricular wall and ventriculardilation. The number of apoptotic cells is dramatically higher in h

10、earts of Doxorubicin-treated C57BL/6 mice(26.447.72%) compared with hearts from control mice (2.550.65%) as demonstrated by TUNEL staining.Importantly, pretreatment with Astragalus Polysaccharides (APS) attenuates Doxorubicin-inducedcardiomyocyte apoptosis (15.546.06%). Moreover, Western blot analys

11、is reveals that AstragalusPolysaccharides (APS) suppresses Doxorubicin-induced caspase 3 and caspase 9 activation. In addition,Bcl2 protein expression is dramatically upregulated in Astragalus Polysaccharides (APS) pretreated mice 2.PROTOCOLCell Assay 1 Astragalus Polysaccharides (20000-60000 mol/L)

12、 are used. After inducing insulin resistance to 3T3-L1 cell,the effect of Astragalus Polysaccharides (APS) is examined on glucose uptake. Glucose uptake tests of theinsulin resistance resistant 3T3-L1 cells are performed after treatment with Astragalus Polysaccharides (0.01,0.05, 0.1, 0.5, 1, 5, and

13、 10 g/mL) for 60 min to obtain an optimum concentration of AstragalusPolysaccharides (APS). And then, the glucose uptake tests of the insulin-resistant 3T3-L1 cells areperformed after treatment with the optimum concentration of Astragalus Polysaccharides (APS) for 0, 15, 30,60, 120, 240, and 480 min

14、 to further obtain the optimal incubation time. To investigate the effect ofAstragalus Polysaccharides (APS) on insulin sensitivity, the insulin-resistant 3T3-L1 cells are treated with 0.1or 1 g/mL Astragalus Polysaccharides (APS) in the presence of 100 nM insulin for 60 min, and thenfollowed by glu

15、cose uptake tests 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 2 Eight-week-old male C57BL/6 mice are used. Normal control (NC) mice orally receive an equivalent volumeof placebo (saline). Doxorubicin-treated mice (DOX)

16、are injected with a single dose of Doxorubicin dissolvedin normal saline (20mg/kg i.p.) and receive an orally equivalent volume of saline. Doxorubicin plusAstragalus Polysaccharides (APS) treatment mice (DOX+APS) are pretreated with AstragalusPolysaccharides (1.5g/kg) for 3 days by gavage and admini

17、stered Astragalus Polysaccharides (APS) for 3additional days after the injection of the same dose Doxorubicin as the DOX group. The dosage of DOX and2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEAstragalus Polysaccharides (APS) is modified. All of the mice in the 3 groups are euthanized 5 days af

18、ter theinitial injection of Doxorubicin.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻 Br J Pharmacol. 2018 May;175(9):1439-1450.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Ke B, et al. Astragalus polysaccharides attenuates TNF-induced insulin resistance via suppression of miR-721 and activation ofPPAR- and PI3K/AKT in 3T3-L1 adipocytes. Am J Transl Res. 2017 May 15;9(5):2195-2206. eCollection 2017.2. Cao Y, et al. Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity b